The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation
复制标题
DOI：
10.1038/leu.2009.1
复制
发表时间：
2009-06-01
期刊：
影响因子：
11.4
通讯作者：
Corradini, P.
中科院分区：
文献类型：
--
作者：
Farina, L.;Bruno, B.;Corradini, P.
造血细胞移植特异性合并症指数（HCT-CI）已被开发用于识别同种异体移植后死亡风险高的患者。降低强度/非清髓性方案降低了老年和/或重度预治疗患者的非复发死亡率（NRM）。我们进行了一项回顾性研究，以评估HCT-CI是否可以预测203例非霍奇金淋巴瘤患者的临床结局。（NHL; n = 108），霍奇金淋巴瘤（HL; n = 26）和多发性骨髓瘤（MM; n = 69），在接受低强度方案（n = 121）后，从人类白细胞抗原（HLA）匹配的同胞（n = 82）或无关供体（n = 121）移植的患者中，154）或低剂量全身照射为基础的非骨髓清除方案（n = 49）。对于HCT-CI为0、1-2和>= 3的患者，1年时NRM的累积发生率分别为5、16和20%，2年时分别为6、24和27%。多因素分析显示，HCT CI显著预测NRM（HR 1.6，P = 0.03）、总生存期（OS; HR 1.62，P
The hematopoietic cell transplantation specific comorbidity index (HCT-CI) has been developed to identify patients at high risk of mortality after an allograft. Reduced-intensity/non-myeloablative regimens have decreased the non-relapse mortality (NRM) in elderly and/or heavily pretreated patients. We performed a retrospective study to assess whether HCT-CI may predict clinical outcomes in a cohort of 203 patients with non-Hodgkin's (NHL; n = 108), Hodgkin's lymphomas (HL; n = 26), and multiple myeloma (MM; n = 69), who were transplanted from a human leucocyte antigen (HLA)-matched sibling (n = 121) or an unrelated donor (n = 82) after a reduced-intensity regimen (n = 154) or a low-dose total body irradiation-based non-myeloblative regimen (n = 49). Cumulative incidence of NRM was 5, 16 and 20% at 1 year and 6, 24 and 27% at 2 years, for patients with an HCT-CI of 0, 1-2 and >= 3, respectively. By multivariate analysis, HCT-CI significantly predicted NRM (hazard ratio (HR) 1.6, P = 0.03), overall survival (OS; HR = 1.62, P